| Title | Date | PubMed ID |
|---|
| Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol. | 2014 Sep | 24838369 |
| Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3. | 2013 Apr | 23454516 |
| 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3). | 2013 Apr | 23353746 |
| Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. | 2013 Feb 25 | 23165153 |
| N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3. | 2012 Sep 15 | 22897946 |
| Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. | 2012 Sep 13 | 22881866 |
| Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. | 2012 May 15 | 22507964 |
| Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. | 2012 May | 22265960 |
| Structure of AKR1C3 with 3-phenoxybenzoic acid bound. | 2012 Apr 1 | 22505408 |
| Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. | 2012 | 22670171 |